Figure 4.

Systemic efficacy of ramucirumab plus docetaxel for NSCLC. (A) ORR and DCR. (B) Waterfall plot of target lesions. One patient was not evaluated for the target lesion because symptomatic brain metastasis occurred prior to the planned assessment. One patient discontinued the protocol treatment on day 29 because of treatment refusal and was excluded from the analysis. (C) PFS. In total, 14 events occurred during the observation period. The median PFS was 6.3 months (95% CI: 1.9–6.9). (D) OS. Ten events occurred. The median OS was 10.4 months (95% CI: 3.2–16.5). NSCLC, non-small cell lung cancer; CI, confidence interval; OS, overall survival; PFS, progression-free survival; ORR, overall response rate; DCR, disease-control rate.